Morphological features and molecular markers in rectal cancer from 95 patients included in the European Organisation for Research and Treatment of Cancer 22921 trial: Prognostic value and effects of preoperative radio (chemo) therapy

European Journal of Cancer

Volumn 44, Issue 6, 2008, Pages 791-797

  Debucquoy, Annelies ^a   Libbrecht, Louis ^a   Roobrouck, Valerie ^a   Goethals, Laurence ^b   McBride, William ^c   Haustermans, Karin ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b AZ Groeninge ^*  (Belgium)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclo oxygenase 2; Cytokeratin 18; Ki67; Predictive; Prognostic; Rectal cancer; Tissue micro array

Indexed keywords

CYCLOOXYGENASE 2; CYTOKERATIN 18; FLUOROURACIL; FOLINIC ACID; KI 67 ANTIGEN;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; FEMALE; HUMAN; INFLAMMATORY INFILTRATE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; RECTUM CANCER; THERAPY EFFECT; TISSUE MICROARRAY; TISSUE SECTION; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOOXYGENASE 2; DISEASE-FREE SURVIVAL; FIBROSIS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-18; KI-67 ANTIGEN; MIDDLE AGED; PREOPERATIVE CARE; PROCTITIS; PROGNOSIS; PROTEIN ARRAY ANALYSIS; RECTAL NEOPLASMS; RECTUM;

EID: 41849104991     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.02.023     Document Type: Article

References (27)

1. Watanabe T., Kiyomatsu T., Kanazawa T., et al. Chemoradiotherapy for rectal cancer: current status and perspectives. Int J Clin Oncol 9 6 (2004) 475-483
2. Smith F.M., Reynolds J.V., Kay E.W., et al. COX-2 overexpression in pretreatment biopsies predicts response of rectal cancers to neoadjuvant radiochemotherapy. Int J Radiat Oncol Biol Phys 64 2 (2006) 466-472
3. Kargman S., Charleson S., Cartwright M., et al. Characterization of prostaglandin G/H synthase 1 and 2 in rat, dog, monkey, and human gastrointestinal tracts. Gastroenterology 111 2 (1996) 445-454
4. Diaz A., Chepenik K.P., Korn J.H., Reginato A.M., and Jimenez S.A. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor-alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res 241 1 (1998) 222-229
5. Hanahan D., and Weinberg R.A. The hallmarks of cancer. Cell 100 1 (2000) 57-70
6. Gerdes J., Lemke H., Baisch H., Wacker H.H., Schwab U., and Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. J Immunol 133 4 (1984) 1710-1715
7. Brown D.C., and Gatter K.C. Ki67 protein: the immaculate deception?. Histopathology 40 1 (2002) 2-11
8. Hu W., and Kavanagh J.J. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol 4 12 (2003) 721-729
9. Leers M.P., Kolgen W., Bjorklund V., et al. Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187 5 (1999) 567-572
10. Duan W.R., Garner D.S., Williams S.D., Funckes-Shippy C.L., Spath I.S., and Blomme E.A. Comparison of immunohistochemistry for activated caspase-3 and cleaved cytokeratin 18 with the TUNEL method for quantification of apoptosis in histological sections of PC-3 subcutaneous xenografts. J Pathol 199 2 (2003) 221-228
11. de Bruin E.C., van de V., van de P.S., et al. Prognostic value of apoptosis in rectal cancer patients of the dutch total mesorectal excision trial: radiotherapy is redundant in intrinsically high-apoptotic tumors. Clin Cancer Res 12 21 (2006) 6432-6436
12. Marijnen C.A., Nagtegaal I.D., Mulder-Stapel A.A., et al. High intrinsic apoptosis, but not radiation-induced apoptosis, predicts better survival in rectal carcinoma patients. Int J Radiat Oncol Biol Phys 57 2 (2003) 434-443
13. Medich D., McGinty J., Parda D., et al. Preoperative chemoradiotherapy and radical surgery for locally advanced distal rectal adenocarcinoma: pathologic findings and clinical implications. Dis Colon Rectum 44 8 (2001) 1123-1128
14. Onaitis M.W., Noone R.B., Hartwig M., et al. Neoadjuvant chemoradiation for rectal cancer: analysis of clinical outcomes from a 13-year institutional experience. Ann Surg 233 6 (2001) 778-785
15. Ruo L., Tickoo S., Klimstra D.S., et al. Long-term prognostic significance of extent of rectal cancer response to preoperative radiation and chemotherapy. Ann Surg 236 1 (2002) 75-81
16. Valentini V., Coco C., Cellini N., et al. Preoperative chemoradiation with cisplatin and 5-fluorouracil for extraperitoneal T3 rectal cancer: acute toxicity, tumor response, sphincter preservation. Int J Radiat Oncol Biol Phys 45 5 (1999) 1175-1184
17. Shia J., Guillem J.G., Moore H.G., et al. Patterns of morphologic alteration in residual rectal carcinoma following preoperative chemoradiation and their association with long-term outcome. Am J Surg Pathol 28 2 (2004) 215-223
18. Galon J., Costes A., Sanchez-Cabo F., et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313 5795 (2006) 1960-1964
19. Bosset J.F., Collette L., Calais G., et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 355 11 (2006) 1114-1123
20. Dworak O., Keilholz L., and Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12 1 (1997) 19-23
21. Tuynman J.B., Peppelenbosch M.P., and Richel D.J. COX-2 inhibition as a tool to treat and prevent colorectal cancer. Crit Rev Oncol Hematol 52 2 (2004) 81-101
22. Debucquoy A., Goethals L., Geboes K., Roels S., Mc Bride W.H., and Haustermans K. Molecular responses of rectal cancer to preoperative chemoradiation. Radiother Oncol 80 2 (2006) 172-177
23. Watwe V., Javle M., Lawrence D., et al. Cyclooxygenase-2 (COX-2) levels before and after chemotherapy: a study in rectal cancer. Am J Clin Oncol 28 6 (2005) 560-564
24. Petersen S., Haroske G., Hellmich G., Ludwig K., Petersen C., and Eicheler W. COX-2 expression in rectal carcinoma: Immunohistochemical pattern and clinical outcome. Anticancer Res 22 2B (2002) 1225-1230
25. Knutsen A., Adell G., and Sun X.F. Inflammatory infiltration, fibrosis, necrosis and mucinous content in relation to clinicopathological and molecular factors in rectal cancers with or without preoperative radiotherapy. Oncol Rep 16 2 (2006) 321-327
26. Ambrosini-Spaltro A., Salvi F., Betts C.M., et al. Oncocytic modifications in rectal adenocarcinomas after radio and chemotherapy. Virchows Arch 448 4 (2006) 442-448
27. Shia J., Tickoo S.K., Guillem J.G., et al. Increased endocrine cells in treated rectal adenocarcinomas: a possible reflection of endocrine differentiation in tumor cells induced by chemotherapy and radiotherapy. Am J Surg Pathol 26 7 (2002) 863-872